PJ Online | News (3 August 2002)

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 269 No 7209 p147-152
3 August 2002

News summary

Research & Development

Independent pharmacies are "unlikely to survive" Trent researchers claim Independent community pharmacies face a bleak future in which they are unlikely to survive, according to a report published by the Trent Institute for Health Services Research...[more]

Ethics training wins funding bid The consortium set up for advancing the provision of pharmacy law and ethics teaching (APPLET), involving schools of pharmacy from Nottingham, Aston and De Montfort universities, has won funding of £250,000 for its three-year project from the Higher Education Funding Council for England (HEFCE)...[more]

Continuous HRT may protect against endometrial cancer Women who use long-term continuous hormone replacement therapy (HRT) do not have an increased risk of endometrial cancer and may even be protected from the disease, results of a study suggest...[more]

Big multiples get seats on NPA board Moss Pharmacy and Lloydspharmacy are to gain places on the National Pharmaceutical Association's board of management from September...[more]

Reliever inhalers linked to increased asthma deaths Increased risk of death from asthma is associated with excessive use of short-acting beta-agonist inhalers, according to a new study...[more]

SSRI withdrawal reactions highlighted The Committee on Safety of Medicines and the Medicines Control Agency have received more reports of withdrawal reactions associated with the selective serotonin reuptake inhibitor paroxetine (Seroxat) than with any other drug...[more]

Nosebleeds following sildenafil use Two cases of nosebleeds following the use of sildenafil (Viagra) for erectile dysfunction are reported...[more]

Zyban safety update continues to reveal only recognised reactions The latest safety update for bupropion (Zyban) from the Medicines Control Agency shows that up to 24 July, a total of 7,630 reports of suspected adverse reactions have been received via the yellow card scheme in the United Kingdom. All are recognised reactions and are listed in the summary of product characteristics for bupropion...[more]

Third generation pill "not more risky" Third generation oral contraceptive pills do not carry a significantly greater risk of causing venous thromboembolism than second generation contraceptives, a High Court judge has ruled...[more]

Patients with Parkinson's disease should not be started on selegiline The use of selegiline, either alone in early stage Parkinson's disease (PD) or in combination with levodopa for more advanced disease, is not justified in new patients, concludes a review...[more]

Tirofiban similar to abciximab over long-term The two platelet glycoprotein IIb/IIIa inhibitors tirofiban (Aggrastat) and abciximab (ReoPro) have similar long-term beneficial effects for patients who undergo angioplasty for narrowed coronary arteries, a follow-up study has shown...[more]

Controversy over smallpox vaccine The Government has been accused of choosing the wrong strain of smallpox for the emergency vaccine reserve stock it has ordered from Powderject Pharmaceuticals...[more]

Varicella-zoster vaccine launched A vaccine containing live, attenuated varicella-zoster virus, Varilrix, has been launched this week by GlaxoSmithKline. The vaccine was previously available on a named-patient basis...[more]

Are multivitamins beneficial? The beneficial effects of multivitamin preparations have been called into question...[more]

Boots sells Halfords for £427m...[more]

COX-2 safety investigated...[more]

Research and Development

Vasopeptidase inhibitor is an effective treatment for chronic heart failure Omapatrilat, a vasopeptidase inhibitor, is effective in treating heart failure, a new study shows. It reduces all-cause mortality and admission to hospital for chronic heart failure requiring intravenous treatment...[more]

Calcium sensitiser lowers mortality A novel calcium sensitiser, levosimendan (Simdax), lowers mortality and improves cardiac function in patients with low output heart failure, a new study shows...[more]

Therapeutic vaccine controls HIV A therapeutic vaccine, Remune, has been shown to stimulate HIV-specific immune responses in 243 HIV infected subjects taking antiretrovirals...[more]

New drug regimen effective in HIV A drug regimen containing a non-peptide protease inhibitor, tipranavir, has been shown to reduce HIV-1 levels in patients who have previously received multiple protease inhibitor regimens, according to new phase IIb data...[more]

Fusion inhibitor "vital component" of new cocktail therapies for HIV infection A fusion inhibitor, T-20 (enfuvirtide), is expected to be a vital component of new cocktail therapies in children as well as adults with HIV infection, according to Roche and Trimeris, the two companies co-developing the new agent...[more]

Cancer vaccine elicits appropriate immune response in patients A gene-based vaccine in development has shown promise for the treatment of colorectal cancer. The vaccine, TroVax, is being developed by Oxford Biomedica, a biotechnology company...[more]

Drug that modulates glutamate levels promising for Alzheimer's disease Memantine (Axura), a non-competitive receptor antagonist that modulates levels of the neurotransmitter glutamate, looks promising for the treatment of Alzheimer's disease, new data show...[more]

New cream for eczema prevents flare-ups in infants Pimecrolimus (Elidel), an anti-inflammatory cream in development, prevents flare-ups of atopic eczema in children as young as three months, according to new data presented at the 2002 World Congress of Dermatology, held in Paris, France, last month...[more]

Back to Top

  * PDF files on PJ Online require Acrobat Reader 4 or later.

Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Salvadore

Citation: The Salvadore URI: 20007408

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy Registration Assessment Questions 3

    Pharmacy Registration Assessment Questions 3 is the third volume in a series that follows on from the previous, highly popular Pharmacy Registration Assessment Questions 2. It features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.


Виагра 150 мг